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Background: A peptide, implicated in Alzheimer disease, occurs in various lengths.
Results: Non-abundant A1–38 and A1–43 affect oligomerization, cytotoxicity, and aggregation of A1–40 and A1–42.
Conclusion: Small amounts of A lengths other than A1–40 or A1–42 significantly alter the behavior of the total A pool.
Significance: Drug strategies targeting APP processing to affect A1–38 levels need careful consideration.
Current therapeutic approaches under development for
Alzheimer disease, including -secretase modulating therapy,
aim at increasing the production of A1–38 and A1–40 at the
costoflongerApeptides.Here,weconsidertheaggregationof
A1–38 and A1–43 in addition to A1–40 and A1–42, in partic-
ulartheirbehaviorinmixturesrepresentingthecomplexinvivo
A pool. We demonstrate that A1–38 and A1–43 aggregate
similar to A1–40 and A1–42, respectively, but display a varia-
tioninthekineticsofassemblyandtoxicityduetodifferencesin
short timescale conformational plasticity. In biologically rele-
vant mixtures of A,A 1–38 and A1–43 significantly affect the
behaviorsofA1–40andA1–42.Theshorttimescaleconforma-
tional flexibility of A1–38 is suggested to be responsible for
enhancing toxicity of A1–40 while exerting a cyto-protective
effect on A1–42. Our results indicate that the complex in vivo
A peptide array and variations thereof is critical in Alzheimer
disease, which can influence the selection of current and new
therapeutic strategies.
Extracellular deposits containing the amyloid- peptide
(A)
3representoneofthehallmarksofAlzheimerdisease(AD)
(1). A is generated from the transmembrane amyloid precur-
sor protein (APP) by - and -secretase-mediated cleavage
(2–4). This action primarily results in the production of the
40-amino acid A1–40 peptide and smaller amounts of the
42-amino acid A1–42 peptide in addition to minute quantities
of other A peptides ranging in length from 27 to 43 amino
acids (5, 6). The observed variation at the A C terminus is a
consequence of the heterogeneous -secretase processing pat-
tern (7) that first generates A1–48 and A1–49 peptides
through cleavage of APP at the -site followed by successive
trimming of every three to four residues (8, 9). Hence, the pref-
erential A1–40 production pathway involves the intermediate
formationofA1–43,A1–46,andA1–49(10).ThearrayofA
peptides that is produced in this way can be affected by clinical
mutations in APP (8, 11) or in the presenilin-1 active site sub-
unit of the -secretase complex (8, 11, 12). Mutations of prese-
nilin-1 potently shift the -cleavage site on APP toward the
A1–38 production pathway with intermediate formation of
A1–42,A 1–45, and A1–48 (10).
Generally,longerApeptidesaremorehydrophobicastheC
termini progressively form part of the transmembrane domain
of APP and are, therefore, considered more aggregation-prone
(13–15). Consistent with this finding, senile plaques have been
found to be primarily composed of A1–42 and A1–43,
whereas shorter A peptides remain largely undetected (16–
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developedthataimedatloweringtheactivityof-secretaseand
reducing A production. However, the multifunctionality of
the -secretase enzyme, including a critical role in the Notch
signaling process, led to the recognition that total inhibition of
this enzyme is an undesired approach. This observation served
as a starting point for the generation of -secretase modulators
(GSMs)thatfine-tunetheactionof-secretasetoshiftthepro-
duction of A peptides toward shorter variants while leaving
the total A peptide production and activity of -secretase
unchanged (19, 20). Given the finding that specifically aggre-
gated A peptide can lead to a neurotoxic response, GSMs
offered in this way a promising perspective as a potential agent
to slow down the progress of senile plaque deposition in AD by
decreasing the production of A1–42 while increasing that of
A1–38. The first generation of GSMs was classified as non-
steroidal anti-inflammatory drugs and derivatives thereof.
Administration of these drugs to healthy individuals showed
positive effects on cognitive function that could be entirely
attributed to the cyclo-oxygenase (COX) inhibitory action of
thecompoundwithoutdisplayingGSMaction(21,22).Clinical
trials with non-COX inhibitory non-steroidal anti-inflamma-
torydrugsdidnotdisplayprotectiveeffectsonADdiseasepro-
gress, possibly as a result of the low potency and poor brain
penetrance of the compounds, inhibition of Notch processing,
oraccumulationofAPPC-terminalfragments(23).Anextgen-
eration of Notch-sparing GSMs and non-steroidal anti-inflam-
matory drug-derived compounds with improved potency and
brain penetration are currently being developed but yet await
clinical trials (22).
The reported neurotoxicity of A1–43 (12) as well as the
observed increasing (24) and decreasing A1–38 (25) levels in
cerebrospinal fluid upon AD progress, indicate that the contri-
butions of A1–38 and A1–43 to AD progression require fur-
therelucidation.Bycomparingtheirpathogenicity,aggregation
profiles, and biophysical properties with that of well studied
A1–40 and A1–42, we show that A1–38 and A1–43 both
form aggregates that differ in cytotoxic potential. We further
show that inclusion of A1–38 and A1–43 into complex mix-
tures containing A1–40 and A1–42 substantially affects the
behavior of total A and that A1–38 and A1–40, previously
considered non-amyloidogenic, can unexpectedly become
toxic in these mixtures. These findings have been related to
conformational plasticity of the respective peptides and high-
lighttherelevanceofunderstandingtheroleofC-terminalvar-
iation of A peptides and their potential as therapeutic targets.
EXPERIMENTAL PROCEDURES
Preparation of A Peptides and Peptide Ratios—A peptides
(rPeptide) were dissolved and mixed as described before (26,
27). Briefly, A was dissolved into 1,1,1,3,3,3-hexafluor-2-pro-
panol, evaporated with an N2 stream, and redissolved in
dimethyl sulfoxide. Solvents were removed by elution over a
5-ml HiTrap desalting column (GE Healthcare) into a 50 mM
Trisbuffer,pH7.4,containing1mMEDTA.Peptideconcentra-
tions were measured using the Coomassie (Bradford) Protein
Assay kit (Thermo Scientific) against a bovine serum albumin
standard (Thermo Scientific). A peptide concentrations were
dilutedtoaconcentrationof50Min50mMTrisbuffer,pH7.4,
containing1mMEDTAandincubatedat25 °Cunderquiescent
conditions for further experiments.
Thioflavin T Fluorescence—Fibrillation kinetics of A in the
presence of 12 M thioflavin T (ThT) were followed in situ at
25 °C using a Fluostar OPTIMA fluorescence plate reader
(BMG LABTECH GmbH) at an excitation wavelength of 440
nm and an emission wavelength of 480 nm. Readings were
recorded in triplicate every 5 min for a period of 10 h and cor-
rected by subtracting the intensity obtained for buffer contain-
ing 12 M ThT. The end of the lag phase was determined man-
ually. Elongation rate was fitted to the central region of the
exponentialphase.Finalfluorescencewasdeterminedat10hof
incubation.
DotBlot—Atvarioustimepointsavolumeof5-lsamplewas
spotted onto Protran BA85 nitrocellulose blotting membrane
(Whatman). The membranes were blocked at 25 °C in phos-
phate-bufferedsalinecontaining0.2%Tween20(PBSTXL)for
1handincubatedfor1hat25°Cwithprimaryrabbitpolyclonal
anti-oligomer antibody (A11) (Invitrogen), diluted 1:4000 in
100 mM Hepes, pH 7.0 (28). After incubation with secondary
anti-rabbit-HRP-tagged antibody (Promega) diluted 1:5000 in
phosphate-buffered saline containing 0.05% Tween 20 (PBST)
for 0.5 h at 25 °C, the membranes were visualized using the
Immobilon
TM Western chemiluminescent HRP substrate sys-
tem (Millipore).
Transmission Electron Microscopy—A volume of 5 lo fA 
wasadsorbedtocarbon-coatedFormvarfilmon400-meshcop-
pergrids(AgarScientificLtd)for1min.Thegridswerewashed
in ultrapure water (Merck) and stained with 1% (w/v) uranyl
acetate (VWR). Samples were studied using a JEOL JEM-2100
microscopeatanacceleratingvoltageof200kVoraJEOLJEM-
1400 microscope at an accelerating voltage of 80 kV (JEOL
Ltd.).
Atomic Force Microscopy (AFM)—AFM imaging was per-
formed on a custom-built instrument using Si3N4 tips (Veeco
Instruments, Woodbury NY; type MSCT-AUHW) with a
springconstantof0.5newtons/mandanominaltipradiusof10
nm.Themeasurementsweremadeintappingmodeinair,with
a tapping amplitude of less than 4 nm. The AFM scan settings
wereoptimizedtominimumforceinteractionwiththesample.
AFM samples were prepared by placing 5 l of sample on
freshlycleavedmica.After4minadsorptiontime,unboundA
was washed off twice with 100 l of ultrapure water (Merck)
anddriedusingagentleN2stream.Theimagesarerepresented
in three-dimensions after removal of height discontinuities
between subsequent scan lines and compensation for piezo
drift using SPIP software (Image Metrology A/S, Lyngby,
Denmark).
Far-UV Circular Dichroism (CD)—After 1.5 h of incubation,
A was diluted to 15 M and placed in a quartz cuvette with an
optical path of 3 mm, and far-UV circular dichroism spectra
were recorded in a Jasco J-715 spectrometer. The wavelength
rangewassetfrom260to190nmwith0.2-nmresolution,2.0-s
response time, 2.0-nm bandwidth at a scanning speed of 50
nm/min. Data were collected as averages of eight scans. The
spectra obtained were corrected by subtracting the spectrum
obtained for buffer only.
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Spectroscopy (ATR FTIR)—Using a Bruker Tensor 27 infrared
spectrophotometer equipped with a Bio-ATR II accessory,
infrared spectra of aggregating A (220 M, 25 °C, in 50 mM
Tris buffer, pH 7.4, containing 1 mM EDTA) were recorded.
The samples were applied to the FTIR sample holder and incu-
batedfor1.5h.Spectrawererecordedintherangeof900–3500
cm
1 at a spectral resolution of 4 cm
1 at the beginning (time
0) and the end (time 1.5 h) of the experiment. Each measure-
ment consisted of 120 accumulations. The spectrophotometer
was continuously purged with dried air. The obtained spectra
were corrected for atmospheric interference, baseline-sub-
tracted, and rescaled in the amide I area (1700 to 1600 cm
1).
Changes of secondary structure over 1.5 h of incubation were
analyzed by subtraction of the spectrum recorded at time 0.
In Silico Predictions—The statistical mechanics algorithm
TANGO (29) was used to predict aggregation-prone regions in
the A peptide sequence (30). TANGO provides an aggrega-
tionpropensity(0–100%)perresidueasoutput.Anaggregating
region is defined as a continuous stretch of residues with an
individual TANGO score higher than 5% and a total score for
the region higher than 50%. Total TANGO scores are calcu-
lated as the sum of the individual residual TANGO scores for a
given sequence. TANGO calculations were performed using
the online TANGO calculator with the following parameters:
pH of 7.0, a temperature of 298.15 K, and 0.02 M ionic strength
without N- or C- terminal protection.
Molecular Dynamics (MD) Simulations—The NMR struc-
ture (Protein Data Bank entry 1IYT) was used as starting struc-
ture of A1–42 and as a template to generate the other A spe-
cies studied here. All MD simulations were performed with
GROMACS 4.5.3 using the OPLS/AA force field (31). Experi-
mentaldetailsaredescribedinthesupplementalmaterials.The
LINCS algorithm (32) was used for bond-length constraining.
The non-bonded pair list was updated every 10 fs. The simula-
tion of each system was repeated at least 10 times and then
individually analyzed, and their averaged properties are
reported here. Programs included in the GROMACS package
as well as some in-house scripts were used to perform the anal-
ysis of the trajectories. Molecular graphics images were pro-
duced using the UCSF Chimera package from the Resource for
Biocomputing,Visualization,andInformaticsattheUniversity
of California, San Francisco (supported by National Institutes
of Health Grant P41 RR001081) (33).
Neuroblastoma Cells and Cytotoxicity—All tissue culture
reagents were obtained from Invitrogen. The human neuro-
blastoma cell line SH-SY5Y (ATCC number CRL-2266) was
cultured in DMEM/F-12 supplemented with 10% fetal bovine
serum (HyClone, ThermoScientific). The cells were incubated
at 37 °C in a humidified 5% CO2 atmosphere. Cytotoxicity
assays were performed in 96-well plates after plating 25,000
cellsperwellinserum-deprivedDMEM/F-12.Afterpre-aggre-
gation for 1.5 h, A was diluted in DMEM/F-12 and added to
the cells. After 24 h of treatment, cell viability was analyzed
using the Cell Titer Blue Cell Viability assay (Promega). After
4 h, color conversion was analyzed by measuring the fluores-
cence intensity of the samples at an excitation wavelength of
544nmandanemissionwavelengthof590nmusingaFluostar
OPTIMA fluorescence plate reader. Values are percent of cell
viability  S.D., and buffer signal was normalized to 100%.
Statistical Analysis—Results from ThT fluorescence and
cytotoxicity experiments were analyzed using two-tailed
unpaired t tests for significance. Significance is indicated by
*** (p  0.0001), ** (p  0.0005), and * (p  0.005). MD results
wereanalyzedusingtwo-wayanalysisofvariancewithrepeated
measurestodeterminewhethereachgroupdifferssignificantly
from each other and multivariate analysis to determine at
which specific point the groups significantly differed. Bonfer-
roni post hoc analysis was applied. Significance is indicated by
##(p0.005).AllpropertiesdeterminedbyMDtechniquesare
reported as the average property of 10 simulations  S.E.
RESULTS
APeptideLengthDeterminesAggregation,Oligomerization,
and Toxicity—It has been reported before that A1–40 and
A1–42 display different aggregation kinetics (13, 34). Consist-
ent with these data, we also observed substantial differences in
aggregation kinetics as a function of peptide length (Fig. 1A)
when comparing A1–38,A 1–40,A 1–42, and A1–43 using
ThT fluorescence. Although A1–38 and A1–40 showed a
delayedonsetofaggregation,A1–42andA1–43rapidlyaggre-
gated, as suggested by the immediate rise in ThT fluorescence
signal. Even though the aggregation regimes of A1–38 and
A1–40 are generally alike, with a distinct lag phase and signif-
icant and sigmoidal development of ThT signal after 10 h of
incubation, A1–38 showed a more rapid onset of aggregation
compared with A1–40. The final (10 h) ThT fluorescence
intensity of both A1–42 and A1–43 aggregates was very low
compared with A1–38 and A1–40 (Fig. 1B) and has been
reported to correlate with the weight concentration and the
morphology of the formed fibrils (35). Transmission electron
microscopy showed that 0.5 h of incubation of A1–42 and
A1–43 resulted in networks of intertwined fibrils, whereas for
A1–38 and A1–40 aggregates were absent (Fig. 1C). Upon
incubation for 4 h, the fibrillar network observed for A1–43
had progressed into polymorphous clusters interconnected by
mature fibrils. A1–42 showed a similar organization, yet short
andalignedfibrilsseemedmoreprevalentcomparedwithA1–
43.Incontrast,A1–38andA1–40bothformedlong,negatively
stainedandregularlytwistedfibrilswithadiameterof8–12nm
that is typically observed for amyloid-like fibrils (36). All A
peptides formed extensive fibrillar networks upon incubation
for24h.ToestablishbywhichmechanismC-terminalvariation
affectedtheobservedaggregationcharacteristicsofA,thesta-
tistical thermodynamics algorithm TANGO was used to pre-
dict aggregating stretches in the various A peptides tested.
TANGO scores further showed that, in general, increasing
aggregation propensity could be observed with increasing pep-
tide length with the exception of A varying in length from 37
to40aminoacids(Fig.1D).Aper-residueanalysisoftheaggre-
gationpropensityshowedthatallAsequencescontainacom-
mon aggregating stretch ranging from residue 16 to residue 22
(37) (Fig. 1E). A second aggregating region starts at residue 28
and spans the remaining C-terminal part of the sequence and
showed strong variation with A length due predominantly to
thepresenceoftwosubsequentglycineresidues,whichdisfavor
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tion promoting residues in the longer forms. Our analysis
shows that differences in aggregation propensity directly stem
from C-terminal variation. In line with our observation that
A1–38 aggregates faster than A1–40 (Fig. 1A), TANGO pre-
dicted a slightly higher aggregation propensity for A1–38 than
for A1–40 (Fig. 1, D and E).
ThT does not interact strongly with oligomeric A (38),
whereas soluble oligomeric A is generally considered to rep-
resent the toxic species (39–41). We used complementary oli-
gomer-sensitive techniques such as the A11 oligomer-specific
antibody(28)andAFMtoobtaininformationonthelifetimeof
oligomeric A as a function of C-terminal variation. A pep-
tides were allowed to aggregate and were tested for A11 reac-
FIGURE 1. C-terminal heterogeneity affects aggregation kinetics of the A peptide. A, ThT fluorescence was recorded in situ every 5 min at 25 °C. A1–38
(continuous black line) and A1–40 (continuous gray line) display a lag phase, whereas A1–42 (dotted black line) and A1–43 (dotted gray line) induce ThT
fluorescencealmostimmediately.Thevaluesrepresentthemeansofthreeexperiments.A.U.,absorbanceunits.B,final(10h)ThTfluorescenceintensitieswas
derivedfrompanelA.Statisticalsignificance(unpaired2-tailedttest)comparedwiththeA1–38valueisindicatedby***(p0.0001),**(p0.0005),or*(p
0.005). C, after 0.5 h of incubation A1–42 and A1–43 formed networks, whereas A1–38 and A1–40 do not show visible aggregates. After4ho fincubation,
A1–38 and A1–40 formed 8–12-nm wide, extended, negatively stained fibrils. A1–42 organized into a network of rigid 14–16-nm wide fibrils. For A1–43,a
mixture of protofibrils and fibrils was observed. After 24 h all As formed similar fibrillar networks. Scale bar, 200 nm. D, total TANGO scores indicated an
increasingoverallaggregationpropensityofAwithincreasingpeptidelength.37–40aminoacid-longpeptidesdeviatedfromthistrend.Peptidesstudiedin
thismanuscriptaremarked.E,sequence-basedpredictionofaggregationpronestretchesbytheTANGOalgorithmsuggestsacommonaggregatingregionin
the core of the peptide and a second aggregating region at the C terminus. Differences in total TANGO score (D) are exclusively due to the C-terminal
aggregating region. A1–38 (continuous black line) and A1–40 (continuous gray line) display similar predicted aggregation propensity, whereas that of A1–42
(dottedblackline)andA1–43(dottedgrayline)werehigher.
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A1–43 formed A11-positive oligomers already after 0.5 h of
incubation, whereas A1–38 and A1–40 only interacted with
the A11-antibody after an incubation time of 5 and 6 h, respec-
tively, with A1–38 exhibiting substantially stronger staining
with the antibody than A1–40. Complementary to A11 reac-
tivity, AFM imaging of samples upon 1.5 h of incubation
showedthepresenceofsmalloligomericspeciesforallApep-
tides tested, including A1–38 and A1–40 (Fig. 2B). Even
though oligomers were present for all A peptides tested,
A1–38andA1–40oligomersonlydevelopedintoA11-positive
oligomers at a later stage compared with A1–42 and A1–43.
Cytotoxicity of oligomeric A upon C-terminal variation was
assessedusingneuroblastomacelllineSH-SY5Y(Fig.2C).A11-
positive oligomers derived from A1–42 and A1–43 induced
loss of cell viability at a concentration of 5 M, whereas those
derived of A1–38 and A1–40 affected cell viability only at a
significantly higher concentration of 20 M.
A Lengths Display Conformational Differences—CD and
FTIR spectroscopy were used to evaluate A structure after
1.5 h of incubation. The spectra recorded for A1–38 and
A1–40 using CD were very similar and displayed typical char-
acteristics of a largely unstructured protein, whereas the spec-
tra of A1–42 and A1–43 showed pronounced -sheet forma-
tion with a minimum intensity at a wavelength of 218 nm (Fig.
3A). As FTIR is more sensitive to -sheet formation than CD
and can distinguish between parallel and anti-parallel -sheet
arrangements, FTIR measurements were performed comple-
mentary to CD. Fig. 3B shows difference spectra obtained by
subtraction of the spectrum of non-aggregated A (time 0)
from the spectrum recorded after 1.5 h of incubation. The
strong increase of absorbance at a wavelength of 1627 cm
1,
concurrent with a loss of signal between 1650–1655 cm
1 and
1680 cm
1 for all four peptides tested, indicated that -sheet
formation took place during the 1.5 h incubation time at the
cost of random coil and -turn structure. The more narrow
peakforA1–38suggeststheformationofamorestable-sheet
as a result of more extensive H-bonding compared with the
other peptide lengths investigated, although A1–40 was found
toformmost-sheetjudgingfromahighersignalintensityata
wavelength of 1627 cm
1. The small increase at 1695 cm
1
seenhereforA1–38andA1–43inadditiontotheincreaseata
wavelength of 1627 cm
1 reveals the formation of an antipar-
allel oriented -sheet that has been typically used as a finger-
print for oligomer formation (42). Variation in evolution of
theseregionsisobservedbetweentheAisoforms.Thisobser-
vation suggests that the various A isoforms display small
structuraldifferencesduringaggregation.EventhoughCDand
FTIRprovideusefulstructuralinformationintermsofanaver-
age of the entire protein sequence, they do not provide insight
into the behavior of individual residues in the sequence and,
hence, are not able to address the question of why the addition
oftwovalinesinA1–40renderedthispeptidelessaggregation-
prone than A1–38. Also, CD and FTIR spectroscopy were
unable to report on short-time scale conformational flexibility
of peptides potentially required to trigger the onset of aggrega-
tion. We used MD simulations to establish whether individual
residues contributed to changes in peptide conformation that
FIGURE 2. Differences in aggregation kinetics due to C-terminal het-
erogeneity are reflected at toxic oligomer levels. A at 50 M was
allowedtoaggregateat25 °Cunderquiescentconditions.A,analysiswith
the A11 oligomer-specific antibody detected oligomeric A1–42 and
A1–43 after as little as 0.5 h of incubation, whereas A1–38 and A1–40
became A11-positive after 5–6 h of incubation. B, imaging using AFM
indicatedthepresenceofoligomersforallAsamplesincubatedfor1.5h.
The length of the bar represents 500 nm. C, preincubated (1.5 h) A was
added to cultured SH-SY5Y cells and incubated for 24 h before probing
cytotoxicity using Cell Titer Blue viability assay. A1–38 (black) and A1–40
(dark gray) only cause cytotoxicity at a concentration of 20 M, whereas
A1–42 (light gray) and A1–43 (white) are significantly cytotoxic at a con-
centration of 5 M. Values are expressed as the percent of cell viability 
S.D. (n  4), and buffer signal was normalized to 100%. Statistical signifi-
cance (unpaired 2-tailed t test) compared with buffer control values (nor-
malized to 100%) is indicated by p value analysis similar to Fig. 1B.
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tions on definition of secondary structure of proteins (DSSP)
analysis(43).Here,wereporttheDSSPresultsas:coil(unstruc-
tured conformation), extended conformation (-bridge plus
-sheet structures), loop (bend plus turns), and helical confor-
mation (-helix plus 310-helix plus -helix). All peptides pre-
sented a general trend to possess a mixture of a collapsed coil
structureandhelicalconformationforresidues1–20.N-termi-
nal helical structure was partially retained over time, whereas
C-terminal helicity, if any, was rapidly lost (supplemental Fig.
1). Also as a general observation, all extended conformations
occurred between residues 21–28 and residues 32 to the C-ter-
minal amino acid. A loop section comprising residues 29–31
formed flexible links between these extended portions. Con-
trary to what was expected, A1–38 conformation behavior
most closely resembled that of A1–42 rather than A1–40 (Fig.
4, A and B, supplemental Fig. 1). Over the 100-ns time scale of
the simulations, A1–38 showed a marked tendency to form
extended conformations (Fig. 4, A and B), comparable with
A1–42 and A1–43 (Fig. 4, B and B1). A1–40, on the other
hand, exhibited low tendency to form extended conformations
(Fig. 4A). Interestingly, during the first 10s of nanoseconds the
behavior of A1–38 was erratic and fluctuated between resem-
bling A1–40 and A1–42/A1–43. Only after 50 ns of simula-
tion did the content of extended conformation invariably
increase (Fig. 4, A and D). A1–42 and A1–43 seemed to accu-
mulate and stabilize better than their extended conformations,
from earlier simulation times onwards (Fig. 4, B and B1, sup-
plementalFig.2).Thesamebehaviorwasreflectedintheoverall
helicity of the peptides (Fig. 4C) revealing a slight, yet statisti-
callysignificant,highertendencytoretainitshelicalconforma-
tionforA1–38incomparisontoA1–42andA1–43.Amarked
increase in the helicity of residues 20–23 and 28 was uniquely
observed for A1–40 (Fig. 4, C and D). Collectively, these data
showed that the behaviors of A1–42 and A1–43 were remark-
ablysimilarintermsoftheirhightendencytoformanextended
-sheetconformation,whereasA1–40retainedhelicitylonger.
The A1–38 peptide showed very interesting behavior in terms
of its highly fluctuating tendency to form extended -sheet
conformation. Over time A1–38 conformation alternated rap-
idly between A1–42/A1–43-like conformation and A1–40-
like conformation before forming a stable, extended -sheet.
Mixtures of A Show Complex Aggregation Behavior—To
evaluate the influence of the observed differences between A
isoforms in a more biologically relevant setting, we mimicked
the complex pool of various A peptide lengths as observed in
vivo by preparing A peptide mixtures containing A1–40,
A1–42andA1–38,orA1–43.IncreasedlevelsofA1–38inthe
cerebrospinalfluidofADpatientsarereported(24)aswellasan
increased generation of this peptide due to presinilin-1 muta-
tions (44). Some forms of familial AD display increased gener-
ation of A1–43 (44), a peptide length frequently present in
amyloid plaques (18). A1–40 and A1–43 were shown to
directlyinteractusingelectrosprayionization-MS(supplemen-
talFig.4C),althoughthesedimericspeciesonlyaccumulatedat
a population of 1% (supplemental Fig. 3C). Effective but low
accumulation of mixed dimers was also observed upon mixing
A1–38 and A1–42 (supplemental Figs. 3B and 4B). Mixed
dimeric complex formation was further detected for A1–38 
A1–40 and A1–42 A1–43 (supplemental Fig. 3 and 4). Along
the lines of the earlier-identified processing pathways of APP
towardtheformationofeitherA1–40andA1–38withA1–43
and A1–42 as intermediates, respectively (10), we mapped
dose-response curves of the presence of A1–43 and A1–38 on
the aggregation kinetics of A1–40 and A1–42, respectively,
using ThT fluorescence (Fig. 5). We reported earlier that
A1–42 A1–40 mixtures behave differently according to their
proportionalpresence(26).TitrationofA1–40withincreasing
concentrationsofA1–43substantiallyreducedthelagphaseof
aggregationtobecomesimilartothatofA1–43alone,whereas
finalfluorescenceintensitieswerenotaffected(Fig.5,A,andC).
These observations suggest that A1–43 dominantly influences
the nucleation process of A1–40, whereas aggregate morphol-
ogy or mass were presumably determined by A1–40 (Fig. 5C).
Titration of A1–38 with A1–42 similarly led to a decreased
nucleationratebut,inaddition,graduallyincreasedtheelonga-
tion rate and final ThT fluorescence intensity (Fig. 5, B and D).
FIGURE 3. Aggregating A peptides show differences on a secondary
structural level. A, CD measurements were performed with preincubated
(1.5 h) A at 15 M. Spectra recorded for A1–38 (continuous black line) and
A1–40 (continuous gray line) were characteristic of peptides with a large
degreeofdisorder,whereasA1–42(dottedblackline)andA1–43(dottedgray
line) displayed curves with a single minimum at 217 nm, suggesting -sheet
formation. High buffer interference was observed at wavelengths 207 nm.
B,FTIRabsorbancewasmeasuredofmonomericandpreincubated(1.5h)A
at 200 M, and the difference between both spectra was plotted. The differ-
ence spectra showed an intensity increase at a wavelength of 1627 cm
1
indicatingthatallfourpeptideswereconvertedintoa-sheetconformation.
For A1–38 (continuous black line) and A1–43 (dotted gray line) an additional
increaseinintensityaround1695cm
1wasobservedimplyinganantiparallel
oriented -sheet. A1–40 (continuous gray line) and A1–42 (dotted black line)
datawerebothcharacterizedbyalossof-turnasobservedbythedecrease
in intensity at 1680 cm
1.
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ofthesepeptidesinisolationarehighlysuggestiveofinteraction
of the A peptides in mixtures.
A1–40isthemostpredominantspeciesrecoveredfromcer-
ebrospinal fluid (6, 45). A1–38 has been reported to be present
in cerebrospinal fluid at concentrations of 1.26 to 2.78 ng/ml,
whereas concentrations of A1–42 were 0.46 to 2.07 ng/ml (6,
45, 46). Quantitative detection of A1–43 has only been per-
formed in brain plaques and, as suitable antibodies are not
available, can generally not be distinguished from that of A1–
42. Although quantitative information on the released amounts
of the four A isoforms of interest from APP is only available
for FAD mutations based on in vitro observations (11, 44, 47,
48), we performed titration assays (Fig. 5). Results indicated
that30%ofA1–38orA1–43alreadycausedasignificantalter-
ationoftheaggregationprofileofA1–42andofthelagphaseof
A1–40. Many FAD-related mutations accumulate A1–42,
whereas it can be assumed that in sporadic AD A1–40 is pre-
dominantly produced (49). We, therefore, decided to evaluate
the effect of small concentrations (10%) of A1–38 and A1–43
on predominantly present (90%) A1–40 and A1–42 to moni-
tor more subtle influences of the presence of peptides in mix-
tures. In summary, we evaluated oligomerization, cytotoxicity,
and aggregation of 9:1 mixtures of A1–40 A1–38,A 1–40 
A1–43,A 1–42 A1–38, and A1–42 A1–43. At these low con-
centrations the effect of the addition of A1–38 and A1–43 to
eitherA1–40orA1–42waslimitedtoasignificantdecreasein
final fluorescence intensity while leaving the nucleation phase
unchanged (Fig. 6, A and B). Visualization of aggregate mor-
phology by transmission electron microscopy further rational-
ized the observed change in final fluorescence intensity (Figs.
1C and 6C). Even though aggregate formation could not be
established at early time points for A1–38 and A1–40 in isola-
tion, a 9:1 mixture of these peptides showed the formation of
extensive ThT-negative but A11-positive aggregates that were
present for extended periods of time (Fig. 6, A, C, and D). Also,
at early time points of incubation the morphologies of both
A1–40 and A1–42 in mixtures (Fig. 6C) appear different from
these peptides in isolation (compare with Fig. 1C). Upon
extended incubation, all mixtures aggregated into morpholog-
ically similar networks of long, interacting fibrils, similar to
thoseobservedforpeptidesinisolation(Fig.6C).Theobserved
differences in A11 interaction and aggregate morphology fur-
therledustoinvestigatethecytotoxicresponseofAmixtures
using cultured SH-SY5Y cells. Interestingly, even though
A1–38 or A1–40 in isolation induced no cytotoxic response
below a concentration of 20 M, the addition of A1–38 to
A1–40 resulted in a pronounced and significant loss of cell
viability at a total peptide concentration of 10 M, consistent
with the A11-positive response for this mixture (Fig. 6, D and
E). Strikingly, the addition of A1–38 to A1–42 instead exerted
a cytoprotective effect despite showing the formation of A11-
positive oligomers, preventing loss of cell viability up to a total
A concentration of 10 M. In addition to this, even though
both A1–42 and A1–43 are similarly cytotoxic at a concentra-
tion of 10 M, the mixture of these two peptides alleviates the
FIGURE 4. A peptides show conformational fluctuations at short time scales that vary upon C-terminal elongation. Secondary structure composition
wasdeterminedbytheDSSPmethod:extendedconformation(-bridgeplus-sheetstructures)andhelicalconformation(-helixplus310-helixplus-helix).
Resultswereaveragedover10independentsimulations.TheextendedconformationcontentinfunctionoftimeforA1–38(continuousblackline)iscompared
with A1–40 (continuous gray line)( A) and A1–42 (dotted black line)( B); the inset plot (B1), A1–43 (dotted gray line), reveals a similar profile compared with
A1–42.Statisticallysignificantdifferences(S.E.)aredenotedby(p0.005(##)).C,thehelicalcontentinthefunctionoftimeisshownforallpeptides.Grayscale
codeisthesameasforthepreviouspanels.Regionsofthesimulationtimewhereintherearestatisticallysignificantdifferencesaredenotedby(p0.005(##))
compared with A1–42. The inset (C1) shows helicity per residue for all A peptides (##, p  0.005, compared with all A peptides). Helicity is reported as the
percentageofsimulationtimethatagivenaminoacidresiduepresented-helixconformation.D,shownaresnapshotsforallApeptidesat0,25,50,75,and
100 ns of simulation time. C termini positions are denoted with an asterisk (*).
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presence of A1–40.
Collectively, our data suggest that, apart from distinct pro-
pensities to form cytotoxic oligomers and aggregates for indi-
vidual A peptides, mixtures of various A peptides do not
behave in a predictable manner according to a simple additive
effect but can actively modulate the behavior of other isoforms
present in the mixture to either induce or prevent toxicity or
modify their aggregation propensities.
DISCUSSION
A aggregation is a complex process during which a mono-
meric population progressively self-assembles first into oligo-
mers and finally into mature fibrils. We show that biologically
relevant mixtures of A peptides containing A1–38,A 1–40,
A1–42, and A1–43 behave in a more complex manner than
can be anticipated from their behaviors in isolation with direct
consequences for their oligomerization, aggregation, and cyto-
toxic behavior. We also report that co-occurring A peptides
can affect each other by conformational modulation of the
C-terminalregionthat,inturn,isafunctionofC-terminalflex-
ibility to adopt various conformations. For example, A1–38 in
isolation exhibited little cytotoxic potential, similar to A1–40.
At the same time, cytotoxic oligomers accumulated rapidly for
A1–42 and A1–43. Nevertheless, mixtures of A1–38 and
A1–40 were highly toxic, whereas the addition of A1–38 to
A1–42 surprisingly induced a cytoprotective effect. The A11
reactivity of the individual A peptides in isolation correlated
with the observed cytotoxicity, although all isoforms were
found to form oligomers. This observation suggests a confor-
mational difference between oligomers of different isoforms.
The presence of both toxic A11-positive and non-toxic A11-
negative oligomers has been reported recently for A as well as
fortheyeast-sup35protein(50,51).Thecytotoxicity-A11reac-
tivitycorrelationforpeptidesinisolationcouldnotbeextended
to mixtures of A isoforms. This lack of correlation can be
explainedbythepolyclonalnatureoftheantibodytorecognize
non-toxic oligomers in addition to toxic species. Another pos-
sibility is that non-toxic and toxic oligomers are both formed
and that the variation in signal intensities and cytotoxicity
arisesfromthevariationinthedistributionbetweentheseolig-
omers. At high concentrations when the level of toxic oligo-
mers is sufficiently high, the shorter A isoforms become sim-
ilar cytotoxic to the longer A isoforms. Although not being
able to reveal distinct accumulation of specific conformations
using CD, FTIR revealed small structural differences during a
1.5-h incubation time. Even though all tested A peptides
showed substantial -sheet formation over time, only for
A1–38 and A1–43 anti-parallel -sheet formation could be
identified that has been interpreted previously as typical for
oligomerformation(42).AsbothFTIRandCDareonlyinform-
ative on an ensemble level, we used MD to elucidate the short-
time scale dynamic behavior of the peptides. MD simulations
revealedthatbothA1–38andA1–42gainedextended-sheet
conformation rapidly, whereas helicity in A1–40 was retained
forlonger,whichisingoodagreementwithearlierreports(52).
In line with our findings, it has previously been reported that
stabilization of the central -helical region of A by ligands or
mutations results in a significant delay of aggregation (53–55)
and that inhibition of unfolding of the central -helical region
increases longevity in a Drosophila model of AD (54). At the
same time, rapid induction of extended -sheet formation has
been found to have a strong predictive power in terms of toxic
potential rationalizing the development of so-called -sheet
breakers as a therapeutic approach (for review, see Ref. 56).
Interestingly, A1–38 showed behavior that could be explained
by rapid gain and loss of extended -sheet conformation, fluc-
tuating in behavior between A1–40 and A1–42/A1–43,
respectively. Rapid conformational switching between distinct
conformations has been observed before for synaptically con-
fined proteins SNAP-25 and synaptobrevin and was proposed
to characterize a specific class of intrinsically disordered pro-
teins(57).Conformationalflexibilitywassuggestedtoallowfor
fast ligand interaction and conformational selection, which
potentially has functional implications for the findings we
report on A1–38 but which warrant further investigation. The
presence of other peptides with higher preference of one over
another conformation may drive A1–38 to rapidly recognize
these as a potential ligand and template for conformational
selection, which in turn either induces or inhibits aggregation.
However, this may be an oversimplification of the actual situa-
tion as A1–42 in the presence of A1–38 is in fact less toxic,
whichdoesnotcomplywiththissuggestion.Furtherresearchis
requiredtopreciselyunderpinthemolecularmechanismofthis
FIGURE 5. Little prevalent A peptides strongly affect the behavior of
predominantA.ThTfluorescencewasrecordedinsituevery5minat25 °C
with 50 M A and 12 M ThT. Values represent the means of two experi-
ments. A and C, irrespective of its concentration, A1–43 (dotted gray line)
reduced the lag phase for aggregation (C1)o fA 1–40 (continuous gray line)
without affecting elongation rates (C2). A1–40 A1–43 mixtures displayed
higherfluorescenceintensityafter8hincubation(C3)thanA1–40andA1–43
alone. Grayscale code is as in A. B and D, titration of A1–42 (dotted black line)
withA1–38(continuousblackline)reducedlagphase(D1)andelongationrate
(D2)butincreasedfluorescenceintensityatplateau(D3).Grayscalecodeisas
in Fig. B. A.U., absorbance units.
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OCTOBER26,2012•VOLUME287•NUMBER44 JOURNALOFBIOLOGICALCHEMISTRY 36739FIGURE6.Apeptidesinmixturesdisplaycomplexaggregationbehaviorandtoxicity.AandB,theadditionof10%(5M)A1–38(continuousblackline)
orA1–43(dottedgrayline)to90%(45M)A1–40(continuousgrayline)orA1–42(dottedblackline)decreasedthefinal(10h)ThTfluorescencecomparedwith
A1–40 or A1–42 alone. Values represent the means of three experiments (C). After 1.5 h of incubation, mixtures containing A1–38 formed amorphous
aggregates,whereasmixturescontainingA1–43formedshortfibrillarstructures.Longerincubationfor6hresultedinfibrillarnetworksforallmixtures,which
extendedintodense,highlyintertwined,stainednetworksafter24hofincubation.Thelengthofthescalebaris200nm.D,allAmixturesintensivelyreacted
with A11 oligomer-specific antibody after 0.5 h of incubation, which gradually decreased upon longer incubation dependent on the A mixture. E,A  was
addedtoculturedSH-SY5Ycellsandincubatedfor24hbeforeprobingcytotoxicityusingtheCellTiterBlueviabilityassay.Notethatnon-toxicA1–40(left,gray)
becamehighlytoxicuponmixingwithnon-toxicA1–38(left,black)andA1–43(left,white)ataconcentrationof10M.ToxicityofA1–42(right,gray)isreduced
upontheadditionofA1–38(right,black)orA1–43(right,white).ValuesarethepercentofcellviabilityS.D.(n4),andbuffersignalwasnormalizedto100%.
Statisticalsignificance(unpaired2-tailedttest)comparedwithbuffercontrolisindicatedby***(p0.0001),**(p0.0005),and*(p0.005).A.U.,absorbance
units.
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36740 JOURNALOFBIOLOGICALCHEMISTRY VOLUME287•NUMBER44•OCTOBER26,2012observation. It has been previously reported that Glu
22, Asp
23,
andLys
28playacriticalroleintheaggregationprocess(58–61).
Presumably, Asp
23 (and Lys
28), although residing in a helical
conformation, may not be able to trigger the formation of
extended conformations, at least at early time points, thus
retarding the aggregation of A1–40. Therefore, not only the
unfolding rate of the C-terminus, as has been previously sug-
gested, can dictate the potential event to trigger aggregation
and toxicity of A (60), but also the capability of a given A
peptide to retain its helical conformation may be considered to
induce such events. Based on the outcome of our MD simula-
tions, we suggest that the plastic behavior of A1–38, inducing
toxicityforA1–40whileeliminatingresponsetoA1–42,plays
a key role to these observations. Hence, the presence of other
peptides may direct the self-assembly process toward at least
two possible pathways, one leading to toxic oligomers and the
second leading to non-toxic intermediates. A1–43 does not
display fluctuating secondary structures and rapidly forms
extended-sheets.Theself-assemblyprocessinthepresenceof
other peptides is, therefore, probably more dependent on the
flexibility of the structure of the second peptide. Indeed, it has
been shown for the N-terminal domain of the HypF protein
from Escherichia coli that both toxic and non-toxic oligomers
can be formed (62).
Overall, our results can be of major importance for the fur-
ther development of therapeutic strategies. The current
approachofmodulating-secretaseactivitytodecreaseA1–42
generation results in increased A1–38 levels at the same time.
This approach is based on the observation that longer A iso-
forms are more aggregation-prone. Hence, establishing an
increased A1–38 level is considered a suitable and non-toxic
approach to inhibit AD disease progress without compromis-
ing the important multi-substrate processing by -secretase.
However, clinical studies still have to confirm their disease-
modulating capacity. Whether this is due to the low brain-bar-
rier penetrating potency of the compounds being tested
requires further investigation. Together with previously pub-
lished data (44), our results possibly indicate that another
explanation for the lack of clinical evidence to place GSMs
firmly on the map as AD therapy may be the induction of
adverse, unexpected events as a result of the increased A1–38
levels in combination with other A peptides. In this view,
Golde et al. (63) recently argued that the efficiency of different
GSMs to shift A release toward shorter isoforms could deter-
minetheirtherapeuticpotential.Weproposethatpeptidecon-
formational flexibility may confer toxic properties to its oligo-
mers and underline the importance of understanding the
interplay between various A isoforms.
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